Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab imbotolimod - Bolt Biotherapeutics

Next Previous
Search
Drug Profile

Trastuzumab imbotolimod - Bolt Biotherapeutics

Alternative Names: BDC-1001; Boltbody™ ISAC BDC-1001

Latest Information Update: 12 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolt Biotherapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; T lymphocyte stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 14 May 2024 Discontinued - Phase-II for HER2-positive-breast-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain, Italy (IV)
  • 14 May 2024 Discontinued - Phase-II for HER2-positive-breast-cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain, Italy (IV)
  • 14 May 2024 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in Italy, France (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top